| Document Date: 2007-04-20 08:28:23
Open Document File Size: 257,76 KBShare Result on Facebook
Company Forum Working Group / The Forum Chemokine Antagonist Working Group / / Country United States / / Event Force Majeure / FDA Phase / Product Issues / / IndustryTerm treatment of HIV / / MedicalCondition HIV infection / tumor / rapid disease / CCR5 deficiency / HIV / lymphoma / opportunistic infections / tumors / infectious diseases / symptomatic infection / HIV-RNA / reduced tumor / unusual infections / infections / West Nile Virus disease / bacterial and viral infections / investigator fatigue / lymphomas / / MedicalTreatment antiretroviral treatment / HAART / antiretroviral therapy / / Organization FDA / Division of Antiviral Drug Product / Food and Drug Administration’s Division of Antiviral Products / / Person John Fry / Veronica Miller / / Position investigator / Executive / Contents Executive / / Product CCR5 / CD4 / immunosurveillance / / Technology pharmacogenomic / Drug Development / / URL www.hivforum.org / /
SocialTag |
FDA/FCHR Collaborative Public Meeting on Long-term Safety Concerns Associated with CCR5 Antagonist Development May 31, 2006 DRAFT REPORT Written by John Fry; Edited by Veronica Miller, on behalf of all presenters and pan